Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma DOI Creative Commons
Rakesh Popat,

Bradley Augustson,

Mercedes Gironella

et al.

Blood Cancer Journal, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 21, 2024

Language: Английский

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma DOI Creative Commons
Rakesh Popat,

Bradley Augustson,

Mercedes Gironella

et al.

Blood Cancer Journal, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 21, 2024

Language: Английский

Citations

0